Antimicrobial Resistance of Nosocomial Pseudomonas aeruginosa Isolates in Russia: Results of National Multicenter Surveillance Study «MARATHON» 2011–2012

Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(4):273-279

Type
Journal article

Abstract

Pseudomonas aeruginosa is the most abundant bacterial species causing nosocomial infections in Russia. In this paper, we report the data on antimicrobial susceptibility of 343 isolates of P. aeruginosa collected in 25 hospitals of 18 cities of Russia in 2011–2012 as part of the national multicenter surveillance study on antimicrobial resistance of nosocomial pathogens, «MARATHON». P. aeruginosa isolates comprised 20.2% of all bacterial nosocomial isolates. Among them, the non-susceptibility rates to main antipseudomonal b-lactams were: 58.9% to cefepime, 60.9% to ceftazidime, 67.1% to piperacillin-tazobactam, 88.0% to imipenem, and 66.8% to meropenem. Production of VIM-type metallo-b-lactamases was detected in 28.3% of the isolates. Most of the isolates were insusceptible to fluoroquinolones: ciprofloxacin (67.6%) and levofloxacin (70.8%), and to aminoglycosides: gentamicin (62.7%), amikacin (57.7%), and tobramycin (50.1%). Polymyxins had the highest in vitro activity with non-susceptibility rates being as low as 3.2% to colistin and 4.7% to polymyxin B. Eleven percent of the isolates had the MIC of fosfomycin exceeding the epidemiological cut-off value of 128 mg/l. Notably, 57.4% of the isolates were categorised as extensively drugresistant (XDR) and 0.3% – as pan-drug-resistant (PDR).

Views
0 Abstract
0 PDF
0 BibTeX
Shared
0
0
0
0
0
0